SYNLAB ("SYNLAB" and “the Group”), the leading medical diagnostic services provider in Europe, announces that the Group acquired 100% of the shares in Yhtyneet Medix Laboratoriot Oy (“YML”), Finland’s leading private laboratory company, from Medix Laboratoriot Oy and Yhtyneet Laboratoriot Oy.
YML offers comprehensive central laboratory services in the fields of clinical chemistry, clinical microbiology, pathology and genetics as well as in therapeutic drug testing, drugs of abuse testing and doping control in sports. Besides the 3 million laboratory tests carried out annually in its central laboratory, YML covers also web-based infectious disease home testing services, point-of-care testing in local laboratories and specimen collection services at customer locations.The takeover of YML is an important corner stone in SYNLAB’s expansion strategy in the Finnish market. After acquiring diagnostic services provider Cityterveys in 2017 which specialises in a variety of imaging and laboratory services, YML now complements SYNLAB’s portfolio in Finland. With the acquisition, SYNLAB strengthens its market position as an independent provider of diagnostic services in Finland, offering high-quality diagnostics to private and public healthcare institutions, occupational healthcare service providers and private individuals.With approximately 150 employees, YML has generated revenues exceeding EUR 18 million in 2017.Mathieu Floreani, CEO SYNLAB Group: “The integration of YML into SYNLAB Group and the resulting synergies will enable us to serve our customers with more comprehensive offerings and a higher proximity. We will benefit from YML’s deep local market expertise to further strengthen our position in the Finnish healthcare sector.”